Tcr2 Therapeutics Inc (TCRR)

The total asset value of Tcr2 Therapeutics Inc (TCRR) stood at $ 199 Mln as on 31-Mar-23

The share price of Tcr2 Therapeutics Inc (TCRR) is $1.48 (NASDAQ) as of 01-Jun-2023 09:30 EST. Tcr2 Therapeutics Inc (TCRR) has given a return of -47.28% in the last 3 years.

Tcr2 Therapeutics Inc (TCRR) has a market capitalisation of $ 58 Mln as on 01-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Tcr2 Therapeutics Inc (TCRR) is 0.22 times as on 01-Jun-2023, a -0.91% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Tcr2 Therapeutics Inc (TCRR) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tcr2 Therapeutics Inc (TCRR) and enter the required number of quantities and click on buy to purchase the shares of Tcr2 Therapeutics Inc (TCRR).

TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

The CEO & director of Dr. Garry E. Menzel M.B.A., Ph.D.. is Tcr2 Therapeutics Inc (TCRR), and CFO & Sr. VP is Dr. Patrick A. Baeuerle Ph.D..

The promoters of Tcr2 Therapeutics Inc (TCRR) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

No, TTM profit after tax of Tcr2 Therapeutics Inc (TCRR) was $-103 Mln.